In a 66-year-old man with Parkinson disease on carbidopa‑levodopa who continues to have freezing episodes, clumsy gait, and upper‑extremity rigidity, which enzyme should be inhibited by an adjunct therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Monoamine Oxidase B (MAO-B) Inhibition is the Indicated Adjunct Therapy

For this patient with Parkinson disease experiencing inadequate symptom control on carbidopa-levodopa alone, adding a monoamine oxidase B (MAO-B) inhibitor is the most appropriate adjunct therapy. The answer is (C) Monoamine oxidase B.

Rationale for MAO-B Inhibition

MAO-B inhibitors (rasagiline, selegiline, safinamide) work by blocking the breakdown of dopamine in the brain, thereby prolonging and enhancing the effects of levodopa. This mechanism directly addresses the patient's persistent motor symptoms—freezing episodes, gait disturbance, and rigidity—that indicate suboptimal dopaminergic stimulation despite carbidopa-levodopa therapy 1.

The evidence strongly supports MAO-B inhibitors as clinically useful adjunct therapy in both early/stable PD and for treating motor fluctuations 1. Specifically:

  • Rasagiline is clinically useful as adjunct therapy in early/stable PD and for motor fluctuations 1
  • Selegiline is clinically useful for monotherapy in early PD 1
  • Safinamide is clinically useful for treating motor fluctuations 1

Why Not the Other Enzyme Targets?

Aromatic L-amino acid decarboxylase (Option A)

This enzyme is already being inhibited by the carbidopa component of the patient's current medication 2. Carbidopa prevents peripheral conversion of levodopa to dopamine, allowing more levodopa to reach the brain. The patient is already receiving 75 mg of carbidopa daily (25 mg three times daily), which saturates peripheral dopa decarboxylase 2. Adding more inhibition here provides no additional benefit.

Dopamine β-hydroxylase (Option B)

This enzyme converts dopamine to norepinephrine. Inhibiting it would be counterproductive in PD, as the goal is to increase dopamine availability, not preserve it by preventing its conversion to norepinephrine.

Phenylethanolamine N-methyltransferase (Option D)

This enzyme converts norepinephrine to epinephrine in the adrenal medulla. It has no role in dopamine metabolism or PD pathophysiology.

Tyrosine hydroxylase (Option E)

This is the rate-limiting enzyme in dopamine synthesis. However, in PD, the problem is loss of dopaminergic neurons, not inadequate tyrosine hydroxylase activity. Inhibiting this enzyme would worsen symptoms.

Alternative Consideration: COMT Inhibitors

While not listed as the correct answer, catechol-O-methyltransferase (COMT) inhibitors (entacapone, opicapone) represent another valid adjunct option for this patient. COMT inhibitors prevent peripheral metabolism of levodopa to 3-O-methyldopa, increasing levodopa bioavailability 3, 4.

  • Entacapone is clinically useful for motor fluctuations 1
  • Opicapone 50 mg daily significantly reduces off-time by approximately 54 minutes compared to placebo 3

However, since COMT is not among the answer choices and MAO-B is option C, MAO-B inhibition remains the correct answer for this examination question.

Clinical Implementation

The patient should be started on a MAO-B inhibitor while continuing carbidopa-levodopa 2. Dosage adjustments of levodopa may be necessary as MAO-B inhibitors enhance dopaminergic effects, potentially causing dyskinesias if the combined effect is excessive 2.

Common pitfall: When adding any adjunct therapy to levodopa, monitor closely for dyskinesias (involuntary movements), which may appear more rapidly with combination therapy and require levodopa dose reduction 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.